50. Dermatomyositis Clinical trials / Disease details


Clinical trials : 182 Drugs : 229 - (DrugBank : 88) / Drug target genes : 48 - Drug target pathways : 147

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000391-15-IT
(EUCTR)
05/06/201827/02/2018Multicentric, prospective open-label study to assess the efficacy and safety of Tocilizumab in subjects with refractory myositisMulticentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis - ToReMy Myositis (dermatomyositis [DM] or polymyositis [PM])
MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
MedDRA version: 20.0;Classification code 10028653;Term: Myositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 20.0;Classification code 10036102;Term: Polymyositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: RoActemra 162 mg soluzione iniettabile in siringa preriempita
Product Name: RoActemra 162 mg soluzione iniettabile in siringa preriempita
Product Code: NA
INN or Proposed INN: Tocilizumab
Other descriptive name: TOCILIZUMAB
Azienda Unità Sanitaria Locale - IRCCS di Reggio EmiliaNULLNot RecruitingFemale: yes
Male: yes
16Phase 2Italy